Cocrystal Pharma (COCP) Other Accumulated Expenses (2017 - 2026)

Cocrystal Pharma (COCP) has 10 years of Other Accumulated Expenses data on file, last reported at $414000.0 in Q1 2026.

• For the quarter ending Q1 2026, Other Accumulated Expenses fell 42.02% year-over-year to $414000.0; the trailing twelve-month figure through Mar 2026 stood at $414000.0 (down 42.02% YoY), and the FY2025 full-year result was $901000.0, up 92.52% from the prior year.
• Other Accumulated Expenses slipped to $414000.0 in Q1 2026, from $901000.0 in the prior quarter.
• In the past five years, Other Accumulated Expenses ranged from a high of $1.7 million in Q4 2023 to a low of $152000.0 in Q1 2023.
• A 5-year average of $557294.1 and a median of $468000.0 in 2024 frame the typical range for Other Accumulated Expenses.
• Across the five-year window, Other Accumulated Expenses sank 80.19% in 2022 and surged 628.88% in 2023, its largest moves.
• Tracing COCP's Other Accumulated Expenses over 5 years: stood at $232000.0 in 2022, then surged by 628.88% to $1.7 million in 2023, then sank by 72.32% to $468000.0 in 2024, then jumped by 92.52% to $901000.0 in 2025, then plunged by 54.05% to $414000.0 in 2026.
• Business Quant data shows COCP's Other Accumulated Expenses at $414000.0 in Q1 2026, $901000.0 in Q4 2025, and $322000.0 in Q3 2025.